High-End Technology Equipment Investment Plan by the National Health System in Spain

30

Jul 2021

On June 30, 2021, it was announced that the Government of Spain, through the Ministry of Health, will invest nearly 400 million euros throughout this year in the development of the High-End Technology Equipment Investment Plan (INVEAT) of the National Health System (SNS) to meet in a planned and orderly way the needs of SNS. The portfolio of equipment to be renewed or expanded has included linear accelerators, CT, magnetic resonance imaging, PET-CT, gamma cameras, digital brachytherapy equipment, vascular angiographs, neuroradiology angiographs, and catheterization laboratories.

The objectives are to reduce the obsolescence of the current SNS technology park and to raise the average density rate of high-tech equipment per 100,000 inhabitants. It is expected that this will increase the overall survival and quality of life through the diagnosis of diseases in the early stages, which, in turn, will enable rapid therapeutic intervention. Special attention is paid to the pathologies with the most significant health impact, such as chronic, oncological, neurological, and rare diseases.

The technological renewal of 100% of the equipment of the SNS that are 12 or more years old and, additionally, of the linear accelerators and CT of 10-11 years (585 units), in line with the recommendations of the scientific societies, was specifically outlined. This way, Spain will be placed in the first positions of compliance with the COCIR "Golden Rules".

In addition, the INVEAT will raise by 17% the average rate of equipment density per 100,000 inhabitants of Spain, advancing progressively towards the European average, expanding the technological park of the SNS by 17% (262 additional units) and, in turn, increasing the percentage of younger equipment. The following increase rates were provided:

  • 67% in PET-CT;
  • 36% in neuroradiology angiographs;
  • 13.4% in MRI;
  • 10.8% in planning CT;
  • 10.3% in hemodynamic equipment;
  • 10% in linear accelerators;
  • 8.5% in digital brachytherapy equipment;
  • 8% in SPECT-CT gamma cameras;
  • 6% in vascular angiographs;
  • 4.3% in CT.

In total, the INVEAT has an investment of 796.1 million euros to be distributed in 2021 and 2022. The renovation of equipment amounts to 585 units and the expansion to 262.

On June 29, 2021, the Interterritorial Council of the National Health System has approved the INVEAT Plan and the agreement of criteria for the distribution of the funds of this investment, which was authorized on June 22, 2021, in the Council of Ministers.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more